0001610717-23-000217.txt : 20230721 0001610717-23-000217.hdr.sgml : 20230721 20230721210601 ACCESSION NUMBER: 0001610717-23-000217 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230720 FILED AS OF DATE: 20230721 DATE AS OF CHANGE: 20230721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martell Bridget A CENTRAL INDEX KEY: 0001629627 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 231103590 MAIL ADDRESS: STREET 1: C/O POINT BIOPHARMA GLOBAL INC. STREET 2: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2023-07-20 0001799448 Aligos Therapeutics, Inc. ALGS 0001629627 Martell Bridget A C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 true false Stock Option (Right to Buy) 1 2023-07-20 4 A 0 20000 0 A 2033-07-20 Common Stock 20000 20000 D The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. /s/ Lucinda Y. Quan, as attorney-in fact for Bridget Martell 2023-07-21